Kenvue Inc. $KVUE Shares Sold by Belpointe Asset Management LLC

Key Points

• Belpointe Asset Management LLC reduced its stake in Kenvue Inc. by 46.8% during the second quarter, selling 34,459 shares and leaving them with a total of 39,202 shares valued at $820,000.
• Kenvue reported $0.29 earnings per share for the last quarter, beating expectations by $0.01, but its revenue of $3.84 billion fell short of the anticipated $3.94 billion.
• The company declared a quarterly dividend of $0.2075 per share, which represents an annualized yield of 5.2%, slightly up from the previous $0.21 dividend.

Belpointe Asset Management LLC lessened its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 46.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,202 shares of the company's stock after selling 34,459 shares during the quarter. Belpointe Asset Management LLC's holdings in Kenvue were worth $820,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Evergreen Wealth Solutions LLC lifted its stake in shares of Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company's stock worth $402,000 after buying an additional 432 shares in the last quarter. Scott & Selber Inc. lifted its stake in shares of Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock worth $2,557,000 after buying an additional 475 shares in the last quarter. Wealth Alliance LLC lifted its stake in shares of Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company's stock worth $762,000 after buying an additional 486 shares in the last quarter. Everett Harris & Co. CA lifted its stake in shares of Kenvue by 1.4% in the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company's stock worth $887,000 after buying an additional 500 shares in the last quarter. Finally, UMB Bank n.a. lifted its stake in shares of Kenvue by 22.3% in the second quarter. UMB Bank n.a. now owns 2,853 shares of the company's stock worth $60,000 after buying an additional 521 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

Shares of KVUE opened at $16.08 on Thursday. Kenvue Inc. has a 1-year low of $15.47 and a 1-year high of $25.17. The stock has a market cap of $30.86 billion, a PE ratio of 21.73, a P/E/G ratio of 2.33 and a beta of 0.72. The firm has a 50-day simple moving average of $19.34 and a two-hundred day simple moving average of $21.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. During the same period last year, the business earned $0.32 earnings per share. The business's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.2%. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is 112.16%.

Analyst Ratings Changes

KVUE has been the topic of a number of analyst reports. The Goldman Sachs Group reduced their target price on shares of Kenvue from $22.00 to $19.00 and set a "neutral" rating on the stock in a research note on Thursday, October 2nd. UBS Group reduced their target price on shares of Kenvue from $23.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday. Barclays reduced their target price on shares of Kenvue from $20.00 to $17.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 1st. Canaccord Genuity Group reduced their target price on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Bank of America reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of "Hold" and an average price target of $21.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.